Chatham Capital Group’s Abiomed Inc ABMD Stock Holding History

Chatham Capital Group’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,985	Closed	-$979K	–	189
2022 Q3	$979K	Hold	3,985	–	–	0.24%	107
2022 Q2	$986K	Buy	+3,985	New	+$1.08M	0.22%	110

Other funds holding ABMD

TRSOTSOK

Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Avion Wealth The Woodlands, Texas $484M AUM 15.17% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Chatham Capital Group's ABMD Position: Q4 2022 in Review

Chatham Capital Group sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 3,985 shares — an estimated $979K sold.

Chatham Capital Group first reported a position in ABMD in Q2 2022 and held it in 2 quarters. The position peaked at $986K in Q2 2022. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

Chatham Capital Group reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
Chatham Capital Group sold 3,985 Abiomed Inc shares in Q4 2022, an estimated $979K.
Chatham Capital Group first reported a position in Abiomed Inc in Q2 2022 and held it in 2 quarters.
Chatham Capital Group's Abiomed Inc position peaked at $986K in Q2 2022.
8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Chatham Capital Group's 13F filing for Q4 2022, filed 1 Feb 2023.